Poor compliance with antifungal drug use guidelines by transplant physicians: A framework for educational guidelines and an international consensus on patient safety

Clinical Transplantation

Volumn 26, Issue 1, 2012, Pages 87-96

  Muñoz, Patricia ^a,b   Rojas, Loreto ^a,b   Cervera, Carlos ^c   Garrido, Gregorio ^d   Fariñas, Maria Carmen ^e   Valerio, Maricela ^a,b   Giannella, Maddalena ^a,b   Bouza, Emilio ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d ORGANIZACIÓN NACIONAL DE TRASPLANTES   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antifungal prophylaxis; Aspergillosis; Aspergillus; Candida; Invasive fungal infections; Solid organ transplant

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; T LYMPHOCYTE ANTIBODY; VORICONAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG CHOICE; EDUCATIONAL STATUS; FOLLOW UP; FUNGAL COLONIZATION; GRAFT REJECTION; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; INVASIVE ASPERGILLOSIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MONOTHERAPY; PARENTERAL NUTRITION; PATIENT COMPLIANCE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SALVAGE THERAPY; T LYMPHOCYTE ACTIVATION;

ANTIFUNGAL AGENTS; DELIVERY OF HEALTH CARE; DRUG PRESCRIPTIONS; GUIDELINE ADHERENCE; HUMANS; INTERNATIONAL AGENCIES; MYCOSES; ORGAN TRANSPLANTATION; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC;

EID: 84856628866     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01405.x     Document Type: Article

References (35)

1. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004: 39: S200.
2. Muñoz P, Alcala L, Sanchez Conde M et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003: 75: 326.
3. Muñoz P, Rodriguez C, Bouza E et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004: 4: 636.
4. Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int 2007: 20: 993.
5. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005: 18: 44.
6. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005: 43: S49.
7. Singh N, Avery RK, Muñoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003: 36: 46.
8. Neofytos D, Fishman JA, Horn D et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010: 12: 220.
9. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010: 50: 1101.
10. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009: 48: 503.
11. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008: 46: 327.
12. Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008: 8: 426.
13. Vandecasteele E, De Waele J, Vandijck D et al. Antimicrobial prophylaxis in liver transplant patients - a multicenter survey endorsed by the European Liver and Intestine Transplant Association. Transpl Int 2010: 23: 182.
14. Husain S, Kwak EJ, Obman A et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004: 4: 796.
15. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008: 46: 1813.
16. Castroagudin JF, Ponton C, Bustamante M et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc 2005: 37: 3965.
17. Brown RS Jr, Lake JR, Katzman BA et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 1996: 61: 666.
18. Fortun J, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002: 8: 1065.
19. Muñoz P, Guinea J, Pelaez T, Duran C, Blanco JL, Bouza E. Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the HEPA air filtration system. Transpl Infect Dis 2004: 6: 50.
20. Bouza E, Pelaez T, Perez-Molina J et al. Demolition of a hospital building by controlled explosion: the impact on filamentous fungal load in internal and external air. J Hosp Infect 2002: 52: 234.
21. Muñoz P, Burillo A, Bouza E. Environmental surveillance and other control measures in the prevention of nosocomial fungal infections. Clin Microbiol Infect 2001: 7: 38.
22. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009: 9: S180.
23. Gavalda J, Len O, San Juan R et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005: 41: 52.
24. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001: 71: 910.
25. Fortun J, Martin-Davila P, Moreno S et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003: 52: 813.
26. Fortun J, Martin-Davila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009: 87: 424.
27. Bouza E, Guinea J, Pelaez T, Perez-Molina J, Alcala L, Muñoz P. Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol 2005: 43: 2075.
28. Clancy CJ, Jaber RA, Leather HL et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007: 45: 1759.
29. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002: 347: 408.
30. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006: 26: 1730.
31. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006: 50: 1570.
32. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008: 46: 201.
33. Groetzner J, Kaczmarek I, Wittwer T et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008: 27: 1.
34. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006: 81: 320.
35. Muñoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006: 19: 365.